Serum cytokine levels of interleukin-1β, -6, -8, tumour necrosis factor-α and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q10, riboflavin and niacin

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 6, 2007, Pages 387-391

  Premkumar, Vummidi Giridhar ^a   Yuvaraj, Srinivasan ^a   Vijayasarathy, Kothandaraman ^b   Gangadaran, Sitthu Govindaswamy Dinakaran ^b   Sachdanandam, Panchanatham ^a  

^a UNIVERSITY OF MADRAS   (India)

^b Government Royapettah Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KANEKA; NICOTINIC ACID; RIBOFLAVIN; TAMOXIFEN; TAMOXIFEN CITRATE; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COENZYMES; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; NIACIN; PROGNOSIS; RIBOFLAVIN; TAMOXIFEN; TUMOR NECROSIS FACTOR-ALPHA; UBIQUINONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMINS;

ZEA MAYS;

EID: 34248674009     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00065.x     Document Type: Article

References (35)

1. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005 5 : 591 602.
2. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornande T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995 87 : 645 51.
3. van Dalen A, Heering KJ, Barak V et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. Breast 1996 5 : 82 8.
4. Perumal SS, Shanthi P, Sachdanandam P. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria. Chem Biol Interact 2005 152 : 49 58.
5. Perumal SS, Shanthi P, Sachdanandam P. Energy-modulating vitamins - a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma. Br J Nutr 2005 93 : 901 9.
6. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003 48 : 82 4.
7. Chopra V, Dinh TV, Hannigan EV. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998 16 : 152 9.
8. McIlhenny C, George WD, Doughty JC. A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers. Br J Cancer 2002 86 : 1786 9.
9. Baselga J, Norton L. Focus on breast cancer. Cancer Cell 2002 1 : 319 22.
10. Hoenjet KM, Dagnelie PC, Delaere KPJ, Wijckmans NEG, Zambon JV, Oosterhof GO. Effect of a nutritional supplement containing vitamin E, selenium, vitamin C and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomized placebo-controlled study. Eur Urol 2005 47 : 433 440.
11. Crane F. The essential functions of coenzyme Q. Clin Invest 1993 71 : S55 59.
12. Nohl H, Gille L, Kozlou AV. Critical aspects of the antioxidant function of coenzyme Q in biomembranes. Biofactors 1999 9 : 155 61.
13. Folkers K, Shizukuishi S, Takemura K et al. Increase in levels of IgG in serum of patients treated with Coenzyme Q10. Res Commun Chem Pathol Pharmacol 1982 38 : 335 8.
14. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 1997 234 : 296 9.
15. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995 212 : 172 7.
16. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994 199 : 1504 8.
17. Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Commun 1993 192 : 241 5.
18. Siassi F, Ghadirian P. Riboflavin deficiency and esophageal cancer: a case control-household study in the Caspian Littoral of Iran. Cancer Detect Prev 2005 29 : 464 9.
19. Pangrekar J, Krishnaswamy K, Jagadeesan V. Effects of riboflavin deficiency and riboflavin administration on carcinogen-DNA binding. Food Chem Toxicol 1993 31 : 745 50.
20. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002 54 : 375 429.
21. Weitberg AB, Corvese D. Niacin prevents DNA strand breakage by adenosine deaminase inhibitors. Biochem Biophys Res Commun 1990 167 : 514 9.
22. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999 19 : 1427 32.
23. Dinarello CA. Interleukin-1. In : Thomas A (ed.). The Cytokine Handbook. Academic Press, San Diego CA, 1998 35 72.
24. Pantschenko AG, Pushkar I, Anderson KH et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 2003 23 : 269 84.
25. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002 2 : 311 5.
26. Jablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jablonski J. TNF-α, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp 2001 49 : 63 9.
27. Benoy IH, Salgado R, Van Dam P et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004 10 : 7157 62.
28. Salven P, Maenpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997 3 : 647 51.
29. Mettler L, Salmassi A, Heyer M, Schmutzier A, Schollmeyer T, Jonat W. Perioperative levels of interleukin-1β and interleukin-6 in women with breast cancer. Clin Exp Obstet Gynecol 2004 31 : 20 2.
30. Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor α correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int J Biol Markers 2004 19 : 130 134.
31. Osborne CK, Elledge RM, Fuqua SAW. Estrogen receptors in breast cancer therapy. Sci Am 1996 3 : 32 41.
32. Arteaga CL, Osborne CK. Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. In : Lippman ME, Dickson RB (eds). Regulatory Mechanisms in Breast Cancer: Advances in Cellular and Molecular Biology of Breast Cancer. Kluwer Academic, Boston, 1991 289 304.
33. Fuller B, Smith D, Howerton A, Kern D. Anti-inflammatory effects of CoQ10 and colorless carotenoids. J Cosmet Dermatol 2006 5 : 30 38.
34. Kodama K, Suzuki M, Toyosawa T, Araki S. Inhibitory mechanisms of highly purified vitamin B2 on the production of proinflammatory cytokine and NO in endotoxin-induced shock in mice. Life Sci 2005 78 : 134 9.
35. Gurujeyalakshmi G, Wang Y, Giri SN. Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-κB in mice. J Pharmacol Exp Ther 2000 293 : 82 90.